Advertisement

Topics

BRIEF-Palatin Technologies announces topline results for phase 3 trials with Bremelanotide

03:44 EDT 23 Sep 2016 | Reuters

* Topline results for phase 3 trials with Bremelanotide for HSDD (Hypoactive Sexual Desire Disorder)are projected to be released early Q4 of calendar year 2016 Source text for Eikon: Further company coverage:

Original Article: BRIEF-Palatin Technologies announces topline results for phase 3 trials with Bremelanotide

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Palatin Technologies announces topline results for phase 3 trials with Bremelanotide"

Quick Search
Advertisement
 

Relevant Topic

Sexual Health
The World Health Organization (WHO) definition of sexual health; "the state of physical, emotional, mental and social well-being related to sexuality; it is not merely the absence of disease, dysfunction and infirmity. Sexual health requires a posit...